A Phase 1 Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-Dose Gemcitabine in Metastatic Pancreatic Adenocarcinoma Patients.
Brandon M HuffmanHanrong FengKalindi ParmarJunning WangKevin S KapnerBose S KochupurakkalDavid B MartignettiGolbahar SadatrezaeiThomas A AbramsLeah H BillerMarios GiannakisKimmie NgAnuj K PatelKimberley J PerezHarshabad SinghDouglas A RubinsonBenjamin L SchlechterElizabeth AndrewsAlison M HanniganStanley DunwellZoe GetchellSrivatsan RaghavanBrian M WolpinCaroline FortierAlan D' AndreaAndrew J AguirreGeoffrey I ShapiroJames M ClearyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
No evidence of clinical activity was observed for combined low dose gemcitabine and LY2880070 in this treatment refractory PDAC cohort. However, the gemcitabine/LY2880070 combination showed in vitro efficacy, suggesting that drug sensitivity for this combination in organoid cultures may not predict clinical benefit in patients.